BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/24/2022 8:11:16 AM | Browse: 783 | Download: 1722
 |
Received |
|
2021-08-12 01:46 |
 |
Peer-Review Started |
|
2021-08-12 01:53 |
 |
First Decision by Editorial Office Director |
|
2021-10-20 21:28 |
 |
Return for Revision |
|
2021-10-20 21:28 |
 |
Revised |
|
2021-11-13 02:01 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2021-12-31 03:38 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2021-12-31 22:18 |
 |
Articles in Press |
|
2021-12-31 22:18 |
 |
Edit the Manuscript by Language Editor |
|
2021-12-29 23:30 |
 |
Typeset the Manuscript |
|
2022-01-11 08:54 |
 |
Publish the Manuscript Online |
|
2022-01-24 08:11 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Rheumatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Rituximab as a treatment for human immunodeficiency virus-associated nemaline myopathy: What does the literature have to tell us?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jucier Gonçalves Júnior and Samuel Katsuyuki Shinjo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jucier Gonçalves Júnior, MD, Academic Research, Division of Rheumatology, São Paulo University, Av. Dr. Arnaldo 3184, 3º Andar-Sala 3131 Cerqueira César, São Paulo 01246-903, Brazil. juciergjunior@hotmail.com |
| Key Words |
Case report; Human immunodeficiency virus; Nemaline myopathy; Rituximab; Rheumatology; Therapy |
| Core Tip |
Rituximab may be a therapeutic possibility for the treatment of Nemaline Myopathies (e.g., human immunodeficiency virus-associated and Monoclonal Gammopathy of Undetermined Significance-associated) because it is less aggressive and has fewer side effects compared to current therapies. Especially in cases of severe visceral involvement. However, the cost and unavailability of therapy can be a limiting factor. |
| Publish Date |
2022-01-24 08:11 |
| Citation |
Gonçalves Júnior J, Shinjo SK. Rituximab as a treatment for human immunodeficiency virus-associated nemaline myopathy: What does the literature have to tell us? World J Clin Cases 2022; 10(4): 1454-1456 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i4/1454.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i4.1454 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.